Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Health Syst Pharm ; 64(14): 1475-82, 2007 Jul 15.
Article in English | MEDLINE | ID: mdl-17617497

ABSTRACT

PURPOSE: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of pregabalin are reviewed. SUMMARY: Pregabalin is the first drug to receive approved labeling from the Food and Drug Administration (FDA) for the treatment of painful diabetic neuropathy and postherpetic neuralgia and is the first antiepileptic agent to receive FDA-approved labeling since 1999. Pregabalin is the pharmacologically active S-enantiomer of racemic 3-isobutyl gamma-aminobutyric acid. Pregabalin has demonstrated efficacy in the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and as adjunctive therapy for adult patients with partial onset seizures. Its exact mechanism of action is unknown. Pregabalin is rapidly absorbed and exhibits linear pharmacokinetics after oral administration. The lack of hepatic metabolism and lack of interaction with cytochrome P-450 isoenzymes explain the absence of drug interactions with pregabalin. Several clinical studies have demonstrated pregabalin's efficacy for each of the FDA-approved indications, with dizziness and somnolence reported as the most common adverse events. Pregabalin has been designated as a Schedule V controlled substance because of its potential for abuse and dependence. The starting dosage for patients with neuropathic pain associated with diabetic peripheral neuropathy is 50 mg three times daily and may be increased to 300 mg daily within one week based on efficacy and tolerability. The starting dosage for patients with partial-onset seizures is 75 mg twice daily or 50 mg three times daily and may be increased to 600 mg daily based on individual response and tolerability. CONCLUSION: Pregabalin may be beneficial for the treatment of neuropathic pain or partial-onset seizures in patients who do not respond to conventional treatments or cannot tolerate their adverse effects.


Subject(s)
Anticonvulsants/therapeutic use , Diabetic Neuropathies/drug therapy , gamma-Aminobutyric Acid/analogs & derivatives , Animals , Anticonvulsants/chemistry , Anticonvulsants/pharmacology , Diabetic Neuropathies/epidemiology , Diabetic Neuropathies/metabolism , Epilepsy, Partial, Sensory/drug therapy , Epilepsy, Partial, Sensory/epidemiology , Epilepsy, Partial, Sensory/metabolism , Humans , Pain/drug therapy , Pain/epidemiology , Pain/metabolism , Pregabalin , gamma-Aminobutyric Acid/chemistry , gamma-Aminobutyric Acid/pharmacology , gamma-Aminobutyric Acid/therapeutic use
2.
Epilepsy Res ; 38(2-3): 139-49, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10642042

ABSTRACT

Patients with mesial temporal lobe epilepsy (mTLE) exhibit marked depressions of the regional cerebral glucose metabolism (rCMRGlu) in the mesiotemporal region. We hypothesised that patients with temporal lobe epilepsy (TLE) who have a bilateral somatosensory or acoustic ( = temporolateral/SII-) aura can be differentiated from mTLE by rCMRGlu depressions primarily involving temporo-perisylvian locations. We therefore used this ictal semiology as a clinical criterion to define a subgroup of such patients and measured the rCMRGlu in 16 patients with TLE as evident from interictal and ictal EEG-video monitoring. Clinically, they presented with medically refractory complex partial seizures and were subjected to presurgical evaluation. The pattern of the interictal rCMRGlu in the TLE patients was different from that observed in patients with mTLE and showed significant depressions ipsilateral to the epileptic focus in mesial temporal and lateral temporal regions but spared the thalamus. The neocortical metabolic depressions were spatially more extended in right than in left TLE patients. Magnetic resonance images (MRI) were either normal (n = 5) or revealed unilateral or bilateral hippocampal atrophy/sclerosis (n = 7), or temporal or extratemporal focal cortical dysplasia (n = 4). The selected TLE patients presented here comprise a heterogeneous group showing most pronounced metabolic depressions in the lateral temporal cortex. Thus, our data suggest that non-invasive metabolic imaging can assist in identifying the neocortical symptomatogenic zone in putative temporo-perisylvian lobe epilepsy.


Subject(s)
Auditory Perceptual Disorders/etiology , Epilepsy, Complex Partial/metabolism , Epilepsy, Partial, Sensory/metabolism , Epilepsy, Temporal Lobe/metabolism , Glucose/metabolism , Temporal Lobe/metabolism , Abdomen , Adolescent , Adult , Atrophy , Auditory Cortex/diagnostic imaging , Auditory Cortex/metabolism , Auditory Cortex/pathology , Child , Dominance, Cerebral , Epilepsy , Epilepsy, Complex Partial/diagnostic imaging , Epilepsy, Complex Partial/pathology , Epilepsy, Generalized/diagnostic imaging , Epilepsy, Generalized/metabolism , Epilepsy, Generalized/pathology , Epilepsy, Partial, Sensory/diagnostic imaging , Epilepsy, Partial, Sensory/pathology , Epilepsy, Temporal Lobe/diagnostic imaging , Epilepsy, Temporal Lobe/pathology , Epilepsy, Tonic-Clonic/diagnostic imaging , Epilepsy, Tonic-Clonic/metabolism , Epilepsy, Tonic-Clonic/pathology , Female , Hippocampus/diagnostic imaging , Hippocampus/pathology , Humans , Magnetic Resonance Imaging , Male , Paresthesia/etiology , Sclerosis , Temporal Lobe/diagnostic imaging , Temporal Lobe/pathology , Tomography, Emission-Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...